Effect of Definition on Incidence and Prognosis of Type 2 Myocardial Infarction

Journal of the American College of Cardiology

Volumn 70, Issue 13, 2017, Pages 1558-1568

  Nestelberger, Thomas ^a,b   Boeddinghaus, Jasper ^a,b   Badertscher, Patrick ^a,b   Twerenbold, Raphael ^a,b,c   Wildi, Karin ^a,b   Breitenbücher, Dominik ^a,b   Sabti, Zaid ^a,b   Puelacher, Christian ^a,b   Rubini Giménez, Maria ^a,b   Kozhuharov, Nikola ^a,b   Strebel, Ivo ^a,b   Sazgary, Lorraine ^a,b   Schneider, Deborah ^a   Jann, Janina ^a   du Fay de Lavallaz, Jeanne ^a,b   Miró, Òscar ^b,d   Martin Sanchez, F Javier ^e   Morawiec, Beata ^f   Kawecki, Damian ^f   Muzyk, Piotr ^f   Keller, Dagmar I ^g   Geigy, Nicolas ^h   Osswald, Stefan ^a   Reichlin, Tobias ^a,b   Mueller, Christian ^a,b   Schumacher, Lukas ⁱ   Shrestha, Samyut ⁱ   Flores, Dayana ⁱ   Rentsch, Katharina ⁱ   López, Beatriz ⁱ   Yañez Palma, M Cecilia ⁱ   Parenica, Jiri ⁱ   Lohrmann, Jens ⁱ   Buser, Andreas ⁱ   more..

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b The GREAT Network   (Italy)

^c UNIVERSITY HEART CENTER HAMBURG   (Germany)

^d HOSPITAL CLÍNIC   (Spain)

^e HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^f MEDICAL UNIVERSITY OF SILESIA   (Poland)

^g UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^h Kantonsspital Liestal   (Switzerland)

ⁱ Kantonsspital Liestal ^*

Author keywords

diagnosis; high sensitivity cardiac troponin; type 2 myocardial infarction

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRIC ACID DERIVATIVE; PHENPROCOUMON; PURINERGIC P2Y RECEPTOR ANTAGONIST; TROPONIN T; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; CARDIOVASCULAR MORTALITY; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DISEASE CLASSIFICATION; DRUG MEGADOSE; DUAL ANTIPLATELET THERAPY; FEMALE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY RATE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; THORAX PAIN; TYPE 1 MYOCARDIAL INFARCTION; TYPE 2 MYOCARDIAL INFARCTION; CLINICAL TRIAL; COHORT ANALYSIS; COMPLICATION; CORONARY ARTERY DISEASE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MYOCARDIAL INFARCTION; SURVIVAL RATE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; COHORT STUDIES; CORONARY ARTERY DISEASE; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROGNOSIS; SURVIVAL RATE;

EID: 85030610678     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2017.07.774     Document Type: Article

References (38)

1. Thygesen, K., Alpert, J.S., Jaffe, A.S., et al. Third universal definition of myocardial infarction. J Am Coll Cardiol 60 (2012), 1581–1598.
2. Lippi, G., Sanchis-Gomar, F., Cervellin, G., Cardiac troponins and mortality in type 1 and 2 myocardial infarction. Clin Chem Lab Med 55 (2017), 181–188.
3. Alpert, J.S., Thygesen, K.A., White, H.D., Jaffe, A.S., Diagnostic and therapeutic implications of type 2 myocardial infarction: review and commentary. Am J Med 127 (2014), 105–108.
4. Thygesen, K., Alpert, J.S., White, H.D., Universal definition of myocardial infarction. J Am Coll Cardiol 50 (2007), 2173–2195.
5. Saaby, L., Poulsen, T.S., Hosbond, S., et al. Classification of myocardial infarction: frequency and features of type 2 myocardial infarction. Am J Med 126 (2013), 789–797.
6. Baron, T., Hambraeus, K., Sundström, J., Erlinge, D., Jernberg, T., Lindahl, B., Type 2 myocardial infarction in clinical practice. Heart 101 (2015), 101–106.
7. Stein, G.Y., Herscovici, G., Korenfeld, R., et al. Type-II myocardial infarction—patient characteristics, management and outcomes. PLoS One, 9, 2014, e84285.
8. Collinson, P., Lindahl, B., Type 2 myocardial infarction: the chimaera of cardiology?. Heart 101 (2015), 1697–1703.
9. Chapman, A.R., Adamson, P.D., Mills, N.L., Assessment and classification of patients with myocardial injury and infarction in clinical practice. Heart 103 (2017), 10–18.
10. Sandoval, Y., Thygesen, K., Myocardial infarction type 2 and myocardial injury. Clin Chem 63 (2017), 101–107.
11. Lindahl, B., Jernberg, T., Badertscher, P., et al. An algorithm for rule-in and rule-out of acute myocardial infarction using a novel troponin I assay. Heart 103 (2017), 125–131.
12. Klinkenberg, L.J.J., Wildi, K., van der Linden, N., et al. Diurnal rhythm of cardiac troponin: consequences for the diagnosis of acute myocardial infarction. Clin Chem 62 (2016), 1602–1611.
13. Hillinger, P., Twerenbold, R., Wildi, K., et al. Gender-specific uncertainties in the diagnosis of acute coronary syndrome. Clin Res Cardiol 106 (2017), 28–37.
14. Twerenbold, R., Jaeger, C., Rubini Gimenez, M., et al. Impact of high-sensitivity cardiac troponin on use of coronary angiography, cardiac stress testing, and time to discharge in suspected acute myocardial infarction. Eur Heart J 37 (2016), 3324–3332.
15. Wildi, K., Nelles, B., Twerenbold, R., et al. Safety and efficacy of the 0 h/3 h protocol for rapid rule out of myocardial infarction. Am Heart J 181 (2016), 16–25.
16. Bossuyt, P.M., Reitsma, J.B., Bruns, D.E., et al. STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. BMJ, 351, 2015, h5527.
17. Haaf, P., Drexler, B., Reichlin, T., et al. High-sensitivity cardiac troponin in the distinction of acute myocardial infarction from acute cardiac noncoronary artery disease. Circulation 126 (2012), 31–40.
18. Thygesen, K., Mair, J., Giannitsis, E., et al. How to use high-sensitivity cardiac troponins in acute cardiac care. Eur Heart J 33 (2012), 2252–2257.
19. Reichlin, T., Irfan, A., Twerenbold, R., et al. Utility of absolute and relative changes in cardiac troponin concentrations in the early diagnosis of acute myocardial infarction. Circulation 124 (2011), 136–145.
20. Vasile, V.C., Saenger, A.K., Kroning, J.M., Jaffe, A.S., Biological and analytical variability of a novel high-sensitivity cardiac troponin T assay. Clin Chem 56 (2010), 1086–1090.
21. Wu, A.H., Lu, Q.A., Todd, J., Moecks, J., Wians, F., Short- and long-term biological variation in cardiac troponin I measured with a high-sensitivity assay: implications for clinical practice. Clin Chem 55 (2009), 52–58.
22. Keller, T., Zeller, T., Peetz, D., et al. Sensitive troponin I assay in early diagnosis of acute myocardial infarction. N Engl J Med 361 (2009), 868–877.
23. Apple, F.S., Pearce, L.A., Smith, S.W., Kaczmarek, J.M., Murakami, M.M., Role of monitoring changes in sensitive cardiac troponin I assay results for early diagnosis of myocardial infarction and prediction of risk of adverse events. Clin Chem 55 (2009), 930–937.
24. Hammarsten, O., Fu, M.L.X., Sigurjonsdottir, R., et al. Troponin T percentiles from a random population sample, emergency room patients and patients with myocardial infarction. Clin Chem 58 (2012), 628–637.
25. Montalescot, G., Sechtem, U., Achenbach, S., et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the Management of Stable Coronary Artery Disease of the European Society of Cardiology. Eur Heart J 34 (2013), 2949–3003.
26. Fihn, S.D., Blankenship, J.C., Alexander, K.P., et al. 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 64 (2014), 1929–1949.
27. Giannitsis, E., Kurz, K., Hallermayer, K., Jarausch, J., Jaffe, A.S., Katus, H.A., Analytical validation of a high-sensitivity cardiac troponin T assay. Clin Chem 56 (2010), 254–261.
28. Levey, A.S., Coresh, J., Greene, T., et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 145 (2006), 247–254.
29. Smilowitz, N.R., Naoulou, B., Sedlis, S.P., Diagnosis and management of type II myocardial infarction: increased demand for a limited supply of evidence. Curr Atheroscler Rep, 17, 2015, 478.
30. Landes, U., Bental, T., Orvin, K., et al. Type 2 myocardial infarction: a descriptive analysis and comparison with type 1 myocardial infarction. J Cardiol 67 (2016), 51–56.
31. Sandoval, Y., Thordsen, S.E., Smith, S.W., et al. Cardiac troponin changes to distinguish type 1 and type 2 myocardial infarction and 180-day mortality risk. Eur Hear J Acute Cardiovasc Care 3 (2014), 317–325.
32. Morrow, D.A., Myocardial Infarction: A Companion to Braunwald's Heart Disease. 2017, Elsevier, St Louis, MO.
33. Guest, T.M., Ramanathan, A.V., Tuteur, P.G., Schechtman, K.B., Ladenson, J.H., Jaffe, A.S., Myocardial injury in critically ill patients. A frequently unrecognized complication. JAMA 273 (1995), 1945–1949.
34. Ostermann, M., Lo, J., Toolan, M., et al. A prospective study of the impact of serial troponin measurements on the diagnosis of myocardial infarction and hospital and 6-month mortality in patients admitted to ICU with non-cardiac diagnoses. Crit Care, 18, 2014, R62.
35. Saaby, L., Poulsen, T.S., Diederichsen, A.C.P., et al. Mortality rate in type 2 myocardial infarction: observations from an unselected hospital cohort. Am J Med 127 (2014), 295–302.
36. Gaggin, H.K., Liu, Y., Lyass, A., et al. Incident type 2 myocardial infarction in a cohort of patients undergoing coronary or peripheral arterial angiography. Circulation 135 (2017), 116–127.
37. Sandoval, Y., Smith, S.W., Thordsen, S.E., Apple, F.S., Supply/demand type 2 myocardial infarction: should we be paying more attention?. J Am Coll Cardiol 63 (2014), 2079–2087.
38. Bonaca, M.P., Wiviott, S.D., Braunwald, E., et al. American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38). Circulation 125 (2012), 577–583.